Tags

Type your tag names separated by a space and hit enter

Baloxavir: First Global Approval.
Drugs. 2018 Apr; 78(6):693-697.D

Abstract

Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Heo YA
Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

MeSH

AdolescentAdultAntiviral AgentsChildDibenzothiepinsDrug ApprovalHumansInfluenza A virusInfluenza B virusInfluenza, HumanJapanMiddle AgedMorpholinesOxazinesPyridinesPyridonesRNA, MessengerThiepinsTriazinesYoung Adult

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29623652

Citation

Heo, Young-A. "Baloxavir: First Global Approval." Drugs, vol. 78, no. 6, 2018, pp. 693-697.
Heo YA. Baloxavir: First Global Approval. Drugs. 2018;78(6):693-697.
Heo, Y. A. (2018). Baloxavir: First Global Approval. Drugs, 78(6), 693-697. https://doi.org/10.1007/s40265-018-0899-1
Heo YA. Baloxavir: First Global Approval. Drugs. 2018;78(6):693-697. PubMed PMID: 29623652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baloxavir: First Global Approval. A1 - Heo,Young-A, PY - 2018/4/7/pubmed PY - 2019/3/15/medline PY - 2018/4/7/entrez SP - 693 EP - 697 JF - Drugs JO - Drugs VL - 78 IS - 6 N2 - Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/29623652/Baloxavir:_First_Global_Approval_ DB - PRIME DP - Unbound Medicine ER -